These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29035537)

  • 1. Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma.
    Yamada K; Brousseau M; Honma W; Iimura A; Imase H; Iwaki Y; Kawanami T; LaSala D; Liang G; Mitani H; Nonomura K; Ohmori O; Pan M; Rigel DF; Umemura I; Yasoshima K; Zhu G; Mogi M
    J Med Chem; 2017 Oct; 60(20):8466-8481. PubMed ID: 29035537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
    Qiao JX; Wang TC; Adam LP; Chen AY; Taylor DS; Yang RZ; Zhuang S; Sleph PG; Li JP; Li D; Yin X; Chang M; Chen XQ; Shen H; Li J; Smith D; Wu DR; Leith L; Harikrishnan LS; Kamau MG; Miller MM; Bilder D; Rampulla R; Li YX; Xu C; Lawrence RM; Poss MA; Levesque P; Gordon DA; Huang CS; Finlay HJ; Wexler RR; Salvati ME
    J Med Chem; 2015 Nov; 58(22):9010-26. PubMed ID: 26524347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel N,N-3-phenyl-3-benzylaminopropionanilides as potent inhibitors of cholesteryl ester transfer protein in vivo.
    Xie H; Li Y; Bai C; Wang R; Liu C; Hao C; Lin B; Cheng M; Zhao D
    Bioorg Med Chem; 2016 Apr; 24(8):1811-8. PubMed ID: 26993745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.
    Trieselmann T; Wagner H; Fuchs K; Hamprecht D; Berta D; Cremonesi P; Streicher R; Luippold G; Volz A; Markert M; Nar H
    J Med Chem; 2014 Nov; 57(21):8766-76. PubMed ID: 25265559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel cholesteryl ester transfer protein inhibitors bearing a cycloalkene scaffold.
    Liu C; Luo C; Hao L; Wu Q; Xie H; Zhao S; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2016 Nov; 123():419-430. PubMed ID: 27490022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.
    Tchoua U; D'Souza W; Mukhamedova N; Blum D; Niesor E; Mizrahi J; Maugeais C; Sviridov D
    Cardiovasc Res; 2008 Mar; 77(4):732-9. PubMed ID: 18056760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
    Filippatos TD; Klouras E; Barkas F; Elisaf M
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
    Sirtori CR
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1543-54. PubMed ID: 21961529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
    Hu X; Dietz JD; Xia C; Knight DR; Loging WT; Smith AH; Yuan H; Perry DA; Keiser J
    Endocrinology; 2009 May; 150(5):2211-9. PubMed ID: 19164467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors.
    Chen D; Huang X; Zhou H; Luo H; Wang P; Chang Y; He X; Ni S; Shen Q; Cao G; Sun H; Wen X; Liu J
    Eur J Med Chem; 2017 Oct; 139():201-213. PubMed ID: 28802120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
    Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
    Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of hydroxyl 1,2-diphenylethanamine analogs as potent cholesterol ester transfer protein inhibitors.
    Jiang J; Finlay H; Johnson JA; Harikrishnan L; Kamau M; Qiao J; Wang T; Adam L; Taylor D; Yang R; Sleph P; Chen AYA; Yin X; Wexler R; Salvati ME
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3278-3281. PubMed ID: 27256912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.